I am a breastfeeding mother and i want to know if it is safe to use Clopentixol cis-(Z)-? Is Clopentixol cis-(Z)- safe for nursing mother and child? Does Clopentixol cis-(Z)- extracts into breast milk? Does Clopentixol cis-(Z)- has any long term or short term side effects on infants? Can Clopentixol cis-(Z)- influence milk supply or can Clopentixol cis-(Z)- decrease milk supply in lactating mothers?
- DrLact safety Score for Clopentixol cis-(Z)- is 1 out of 8 which is considered Safe as per our analyses.
- A safety Score of 1 indicates that usage of Clopentixol cis-(Z)- is mostly safe during lactation for breastfed baby.
- Our study of different scientific research also indicates that Clopentixol cis-(Z)- does not cause any serious side effects in breastfeeding mothers.
- Most of scientific studies and research papers declaring usage of Clopentixol cis-(Z)- safe in breastfeeding are based on normal dosage and may not hold true for higher dosage.
- Score calculated using the DrLact safety Version 1.2 model, this score ranges from 0 to 8 and measures overall safety of drug in lactation. Scores are primarily calculated using publicly available case studies, research papers, other scientific journals and publically available data.
Studies have failed to show any harmful effect on the infant. It is likely to be safer by using it orally on a daily basis than on IV slow-release dosage (depot).
Clopentixol cis-(Z)- is not approved for marketing in the United States by the U.S. Food and Drug Administration, but is available in other countries. Limited information indicates that maternal oral doses of up to 50 mg daily or depot injections of 72 mg every 2 weeks produce low levels in breastmilk and no detectable short-term adverse effects in the breastfed infants. No long-term data are available. Until more data are available, Clopentixol cis-(Z)- should be used with careful monitoring during breastfeeding. One international guideline recommends that women taking Clopentixol cis-(Z)- not breastfeed.[1]
Six women received Clopentixol cis-(Z)- during nursing. Five of the women were receiving 4 to 50 mg daily by mouth and one was receiving a depot injection of 72 mg every 2 weeks. Their breastfed infants range in age from 3 days to 10 months old, 5 of whom were 2 months or under. No immediate adverse effects such infant drowsiness were noted.[2]
Disclaimer:
Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. We do not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.